SALT LAKE CITY–( BUSINESS WIRE )–Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease.
Read the source article at businesswire.com
